Pharmaceutical Sciences Market Analysis and Reports | UK Conference Series

Market Analysis - Pharmaceutical Sciences 2020

Market Research on Pharmaceutical Sciences

The Board of Pharmaceutical Sciences (BPS) of the International Pharmaceutical Federation (FIP) has developed a view on the future of pharmaceutical sciences in 2020. The global pharmaceutical market is projected to reach 10.27 billion USD by 2025. The market is expected to see a growth at 13.1% CAGR owing to increasing incidence of Adverse Drug Reaction. The key driver for the growth of the pharmaceutical market is ADR’s. In 2015, the U.S. FDA received almost 253,017 serious adverse events and 44,693 deaths associated with adverse drug reactions (ADRs). This shows the possible demand for instigating safety and pharma services. The statistic shows the projected growth of the world pharmaceutical market by the regional group between 2018 and 2022. It is expected that the pharmaceutical market will have a compound annual growth rate of 6 to 9 percent in this period.

This statistic describes the projected global pharmaceutical market growth for the period 2016-2021, measured by the compound annual growth rate (CAGR) and sorted by regional submarkets. It is expected that North America will grow at a CAGR of 4.3 percent.

The global market for natural & plant-derived drugs was valued at $23.2 billion in 2013 and $24.4 billion in 2014. This total market is expected to reach $35.4 billion in 2020, with a Compound Annual Growth Rate (CAGR) of 6.6% from 2015 to 2020.

Pharmaceuticals represented a US$300 bn-a-year market globally as of 2015, the World Health Organization states. The global pharmaceutical market is expected to surpass US$400 bn by 2018. Worldwide prescription drug sales forecasted to grow at a robust 6.5% (CAGR) through 2022 to reach $1.06trn. 32% of the 2022 increase in sales to come from orphan drugs (+$95bn).

Major Pharma Associations around the Globe:

The Pharmaceutical Industry: A Key Asset to The European Economy

As driving medical progress by researching, developing and bringing new medicines that improve health and quality of life for patients around the world, the research-based pharmaceutical industry is a key asset of the European economy. It is one of Europe’s top performing high technology sectors.


 All new medicines introduced into the market are the result of lengthy, costly and risky research and development (R&D) conducted by pharmaceutical companies: Certain key factors that decide the market value of a pharmaceutical product are:

■ by the time a medicinal product reaches the market, an average of 12-13 years will have elapsed since the first synthesis of the new active substance;

■ The cost of researching and developing a new chemical or biological entity was estimated at € 1,172 million ($ 1,506 million in year 2011 dollars) in 2012 (Mestre-ferrandiz et al, office of Health Economics, December 2012);

■ on average, only one to two of every 10,000 substances synthesised in laboratories will successfully pass all stages of development required to become a marketable medicine.

Hence the value of the product is set accordingly keeping in mind all such factors.

The value of pharmaceutical research based on the amount of research funding in different countries in Europe can be compared from the table below

EfpIA 2012 € million












Czech  Republic


















































United Kingdom





In 2012 the pharmaceutical industry invested more than € 30,000 million in R&D in Europe. A decade of strong uS market dominance led to a shift of economic and research activity towards the uS from 1995-2005. Additionally, Europe is now facing increasing competition from emerging economies: rapid growth in the market and research environments in countries such as brazil and china are contributing to the move of economic and research activities to non-European markets. The geographical balance of the pharmaceutical market – and ultimately the R&D base – is likely to shift gradually towards emerging economies

Pharmaceutical R&D Expenditure - Annual Growth Rate %


The world pharmaceutical market was worth an estimated € 655,222 million ($ 870,200 million) at ex-factory prices in 2013. The north american market (usa&canada) remained the world’s largest market with a 41.0% share, well ahead of europe and japan.

Breakdown of the World Pharmaceutical Market – 2013 Sales


Distribution margins, which are generally fixed by governments, and vat rates differ significantly from country to country in Europe. On average, approximately 34% of the retail price of a medicine reverts not to the manufacturer, but rather to the distributors (pharmacists and wholesalers) and the state.

Breakdown of the Retail Price Of A Medicine, 2012 (%)

The pharmaceutical industry comprises of companies that are engaged in research, development, manufacture and distribution drugs for human or veterinary use. The primary function of the research-based pharmaceutical corporations is to create value by discovering and producing effective medicines, vaccines and services that improve patients’ well-being, and can be sold in markets at a profit. As well as increasing shareholder value, this contributes significantly to the quality and protection of life and helps make the world a better place. In the past 60 years, innovation and technology have driven huge improvements in global health.

The pharmaceutical industry is undergoing a tremendous deal of change. There are many pharmaceutical companies, who are providing the better products. The Pharma industry is one of the most sought after, and flourished industries. As the pharmaceutical drug manufacturers are one of the reasons for the economic well being of a nation. On the other hand, we can say that the Pharma industry is responsible for the economic development. That is the main reason for both research and development of newer and better products for various kinds of diseases.

Top Pharma companies around the Globe:

As a highly specialized production location for pharmaceutical products, Switzerland enjoys an excellent reputation the world over. The presence of highly qualified scientists and pharmaceutical talent from the world’s leading universities make a significant contribution towards developing new medicines. The framework conditions are also in place: the Swiss healthcare system supports the introduction of new medicines and, in doing so, offers companies access to a sophisticated test and sales market. In addition to Switzerland, international markets play a decisive role. Value added in the pharmaceutical industry has continued to increase over the last decade in Switzerland. Switzerland is by far the most important stock exchange for Life Sciences companies in Europe.

Global Pharmaceutical Industry 2013-2018: Trend, Profit, and Forecast Analysis

The global pharmaceutical industry revenue is forecasted to reach an estimated $1,226.0 billion by 2018, with good growth over the next five years (2013-2018). The industry is expected to register growth led by aging population, changing lifestyles, hectic daily activities, unhealthy eating habits, increasing incidence of chronic diseases across the entire global population providing growth opportunities for the industry players.

The industry is engaged in discovery, development, manufacture, and marketing of prescription drugs. Industry products include ethical drugs and consumer healthcare but animal healthcare drugs are not included.
The global pharmaceutical market faces major challenge from increasing investment and strict regulation. Changing lifestyles and the fast socio-demographic shift due to urbanization in both developed and growth markets globally are expected drive the demand. The ability to create new technology and innovative drugs is a key driver for success in this market. 
North America is projected to lead the pharmaceutical industry. Vaccine industry is expected to record the highest growth during the forecast period. ROW industry is expected to witness the highest growth during 2013-2018. Government initiatives in Brazil to encourage drugs industries by providing free pricing policies and special financial investment options will attract the industry players. APAC holds good growth potential for the future.
This study provides an overview of the global pharmaceutical industry by tracking 13 market segments of that industry in four geographic regions. Thus, a total of 52 segments of the global pharmaceutical industry are tracked. The report studies manufacturers of bone, respiratory, immunology and dermatology, cardiovascular, diabetes & obesity, urinary/kidney diseases, gastrointestinal, neurosciences, infectious diseases, ophthalmology, oncology, women’s health/ endocrine, vaccines, consumer health/OTC, and others providing a five-year (2007-2012) annual trend analysis that highlights market size, profit and cost structure for NA, Europe, APAC, and ROW. The report also provides a forecast, addressing market opportunities for next five years (2013-2018) for each of these regions. 

This comprehensive guide provides readers with valuable information and the tools needed to successfully drive critical business decisions with a thorough understanding of the market’s potential. This report will save clients hundreds of hours in personal research time on a global market and it offers significant benefits in expanding business opportunities throughout the global pharmaceutical industry analysis. In a fast-paced ever-changing world, business leaders need every advantage available to them in a timely manner to drive change in the market and to stay ahead of their competition. This report provides business leaders with a keen advantage in this regard by making them aware of emerging trends and demand requirements on an annual basis. 

Features and Scope of this Report:

To make any investment or strategic decision, you need adequate and timely information. This market report fulfils this core need. Some of the features of this market report are:

- Industry size estimates in terms of (US $) value by regions and by segments
- Global pharmaceutical industry annual trend (2007-2012) and forecast (2013-2018)
- Porter’s Five Force analysis
- New product launch, merger and acquisition activity in global pharmaceutical industry
- Quarterly demand trend (Q1 2011-Q4 2012) and forecast analysis (Q1 2013-Q4 2014) for pharmaceutical industry analysis
- Gross and net profit trends in the global pharmaceutical industry
- Cost structure trend in the global as well as regional pharmaceutical industry

Market Analysis of Global Pharmaceutical Industries:

The global $1.12 trillion market in 2022, will rise at a faster clip during 2016-2020, then slow down a bit as major patent expiration take hold. It is expected that the global market declined by 1.0% in 2015, but will grow by 4.8% this year. Prescription sales excluding generics will rise 4.4% this year, and expected to reach $1.006 trillion in 2022. Generics sales will increase from $73 billion in 2015 to $115 billion in 2022, and constitute 10.2% of prescription sales at that point only 0.3 percentage points more than it is now.

The global market for drug discovery technologies and products was worth $38.4 billion in 2011. This figure is projected to reach $41.4 billion in 2012 and $79 billion in 2017, a five-year compound annual growth rate (CAGR) of 13.8%. There is a need to impede serious adverse effects caused by the drugs by enhancing drug targeting through research in pharmacology.

The global revenue for single use technology reached $1.4 billion and $1.7 billion in 2013 and 2014, respectively. This market is expected to grow at a compound annual growth rate (CAGR) of 11.7% to nearly $3.0 billion for the period 2014-2019.

The fast-growing division of the pharmaceutical market includes generics and biologics. Biologics now account for over a third of all new drugs in clinical trials or awaiting FDA approval.15 U.S generic drug sales reached an estimated $70 billion, representing a quarter of the global market, due to a large number of drugs going off-patent and healthcare reforms favoring generics. Although generics make up only 22 percent of total prescription sales, its share of filled prescriptions has risen from 19 percent in 1984 to 88 percent in 2015. The research-based pharmaceutical industry is estimated to have spent nearly USD 149.8 billion globally on pharmaceutical R&D in 2015-16. Among all the industrial sectors, the research-based pharmaceutical industry has consistently invested the most in research and development, even in times of economic turmoil and monetary crisis.

According to the Quintiles IMS Institute predicts that the pharmaceutical market by 2021 will reach nearly USD 1,485 billion, by an increase of USD 350-380 billion from the USD 1,105 billion recorded in 2016. Global brand spending is forecast to increase to USD 815-832 billion in 2021. Global generic spending is expected to increase to USD 495-505 billion by 2021.

The United States share of global spending will increase from USD 461.7 billion in 2016 to USD 645-675 billion in 2021, while the European share of spending will grow from USD 151.8 billion to USD 170-200 billion. Meanwhile, pharmerging countries will spend nearly 315-345 USD billion in 2021 from 242.9 in 2016.

Glance at Market of Pharma:

These data describe the outcome of the patient as defined in U.S reporting regulations. Serious means that one or more of the following outcomes were documented in the report: death, hospitalization, life threatening. There is a need to impede serious adverse effects caused by the drugs by enhancing drug targeting through research in pharmacy.

The Changing Geography of Pharma Markets

Growth over past decades means that North America and Western Europe still account for 56% of the global market, but Asia Pacific has overtaken Western Europe as the second largest region. Growth in Asia Pacific is fueled by increased affordability of drugs resulting from the launch of low-priced generics. Other factors that are positive for growth in Asia Pacific are the rise of GDP per capita in the region, government programs to support healthcare, and rapid urbanization, which brings both doctors and pharmacies within easy reach of increasing proportions of growing populations. Pharma sales in Asia Pacific will grow at 8.4% a year to 2021.

The story is a similar one at the level of country. The USA, by itself worth 25% of the global total, is restraining global growth by rising at below 5% a year, while the much smaller pharma markets of India and China are both achieving double that pace.

Key Segments in the Pharmaceutical Market

The largest pharma market globally is for musculoskeletal drugs. These are treatments for diseases such as rheumatoid- and osteo- arthritis, osteoporosis, carpal tunnel syndrome, tendonitis, rotator cuff tear, muscular dystrophy, myasthenia gravis, lupus erythematosus and others. Major drugs in this segment include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer. The segment accounted for 14% of the global total in 2017. Cardiovascular, oncology and ant-infective drugs are the second third and fourth largest markets.

Drugs for treating metabolic disorders such as diabetes and diseases of the thyroid and pituitary glands will be the fastest-growing segment of the global pharma market to 2021. This segment will grow at 9% a year going forward, following recent growth of 11.6%, but it will remain in fifth place for market size

Dear Visitors,

Welcome to the “20th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry” Conference at London, UK during April 01-02, 2020.

The Conference will carry out upon the theme “New Challenges in Pharma Industries and Growth of Pharmaceutical Research

We would like to welcome Professors, Doctors, Young Researchers, Society and Association members across the Globe, Doctors, Business development professionals, Consultants and Pharma service providers, PhD scholars, Students and interested participants.

You will be getting an opportunity towards;

  • Keynote Presentations
  • Oral Presentations
  • Poster Presentations
  • Workshops
  • Symposia
  • Young Researchers Forum (YRF)
  • Video Presentations
  • E-posters
  • Exhibitions
  • Sponsorship
  • Collaborations

Motives to attend:

Keynote presentation along with interactions to galvanize the scientific community.

Workshop and symposiums to reach the largest assemblage of participants from the Pharma community.

A wide track of exhibitors to showcase the new and emerging technologies.

Platform to global investment community to connect with stakeholders in Pharma sector.

Young Scientist/ Investigators Award geared towards best budding young research.

Links to the political marketing resources  in order to expand your business and research network.

Triumph of Awards, Certificates recognizes your commitment to your profession to encourage the nascent research.

Target Audience:

  • Researchers
  • Directors, CEO’s of Organizations
  • Scholars from Pharmaceutical backgrounds
  • Drug Delivery Technology Manufacturers
  • Business Development Managers
  • Distributors and Suppliers of Drug Delivery Technologies
  • Students, Professors, Researchers, and Faculty of Pharmaceutical Sciences from Universities and Medical Colleges
  • Researchers from Pharmaceutical Companies, Pharmacy Associations and Societies
  • Health professionalsPharmacists
  • Business development professionals, Consultants and Pharma service providers
  • Quality control specialist
  • Graduates and post graduates in industrial pharmacy
  • Medical Devices Manufacturing Companies, CRO
  • Data Management Companies.
  • Pharmaceutical legislators and regulators

Why to attend?
20th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry Pharmaceutical Conference 2020 is among the world's leading pharmaceutical conference. The two-day occasion on pharmaceutical sciences will have 60+ logical and particular sessions and sub-sessions on innovative researches in the field of pharmaceutical sciences over the globe. Pharmaceutical conference 2020 will involve 16 imperative sessions proposed to offer broad sessions that states issues in the diverse fields of research and pharmaceutical sciences.

The attendees can find exclusive sessions and panel discussions on the growth of pharmaceutical research.

  • Lectures from renowned speakers
  • Keynote forums by Prominent Professors, Doctors
  • Open Innovation Challenges
  • Poster presentations by Young Researchers
  • Global Networking sessions with 50+ Countries
  • Novel techniques to benefit your research
  • Best platform for Global business and Networking opportunities
  • Meet the editors of referred journals, Society and Association members across the Globe
  • Excellent platform to showcase the latest products and formulations in Pharma Care